CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer in Korea
Seung Hoon Beom, Jisu Oh, Tae-Yong Kim, Kyung-Hun Lee, Yaewon Yang, Koung Jin Suh, Hyeong-Gon Moon, Sae-Won Han, Do-Youn Oh, Wonshik Han, Tae-You Kim, Dong-Young Noh, Seock-Ah Im
Cancer Research and Treatment. 2017;49(2):454-463.   Published online 2016 August 23    DOI: https://doi.org/10.4143/crt.2016.259

Excel Download

417 POSTER Maintenance hormone therapy with letrozole after first-line chemotherapy in postmenopausal patients with hormone receptor-positive metastatic breast cancer
European Journal of Cancer Supplements. 2005;3(2):117   Crossref logo
Link1 Link2

PCN160 COST-EFFECTIVENESS OF RIBOCICLIB PLUS LETROZOLE COMPARED TO PALBOCICLIB PLUS LETROZOLE IN THE FIRST-LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HR+/HER2-) ADVANCED OR METASTATIC BREAST CANCER (ABC): A BRAZILIAN PRIVATE PAYER PERSPECTIVE
Value in Health. 2019;22:S466-S467   Crossref logo
Link1 Link2

Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer in Korea
Cancer Research and Treatment. 2017;49(2):454-463   Crossref logo
Link1 Link2 Link3

Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer
Breast Cancer Research and Treatment. 2008;112(S1):53-66   Crossref logo
Link1 Link2 Link3

Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer – Results of the eLEcTRA trial
The Breast. 2012;21(1):27-33   Crossref logo
Link1 Link2

POSA116 Cost-Utility of Ribociclib As the First-Line Treatment in Postmenopausal Women with Advanced/Metastatic Breast Cancer, Hormone Receptor Positive and Human Epidermal Growth Factor Receptor-2 Negative in Colombia
Value in Health. 2022;25(1):S56   Crossref logo
Link1 Link2

First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis
Breast Cancer. 2020;27(3):340-346   Crossref logo
Link1 Link2 Link3

EE372 Cost-Utility of Ribociclib As the First-Line Treatment in Postmenopausal Women with Hormone Receptor Positive and Human Epidermal Growth Factor Receptor-2 Negative Advanced/Metastatic Breast Cancer in Colombia
Value in Health. 2022;25(7):S408   Crossref logo
Link1 Link2

Letrozole in First-Line Therapy of Advanced Breast Cancer in Postmenopausal Women Is Superior to Tamoxifen
Clinical Breast Cancer. 2001;1(4):272-273   Crossref logo
Link1 Link2

Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor–Positive Metastatic Breast Cancer
The Oncologist. 2010;15(3):327-327   Crossref logo
Link1 Link2 Link3 Link4

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.